Specifically, PIM-1 overexpression has been observed in diffuse large B-cell lymphoma (DLBCL), acute myeloid leukemia (AML), and chronic lymphocytic leukemia (CLL), correlating with advanced disease stages and reduced survival rates. Here, PIM1 is linked to B-cell chronic lymphocytic leukemia.